Mirati Therapeutics Growth, Revenue, Number of Employees and Funding

Overview

Location:
Total Funding:$101.3M
Industry:Biotech
Founded:2013
Lead Investor(s):Cowen, Barclays
Press

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Mirati Therapeutics's estimated revenue is currently $12.9M per year.
  • Mirati Therapeutics received $130.0M in venture funding in January 2019.
  • Mirati Therapeutics's estimated revenue per employee is $187333
  • Mirati Therapeutics's total funding is $101.3M.

Employee Data

  • Mirati Therapeutics has 69 Employees.
  • Mirati Therapeutics grew their employee count by 33% last year.
  • Mirati Therapeutics currently has 9 job openings.

What Is Mirati Therapeutics?

Mirati Therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. Mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. The Mirati team uses a blueprint - proven by their prior work - for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. Mirati is advancing three drug candidates through clinical development for multiple oncology indications.

keywords:Biotechnology,Healthcare,Marketing,Pharmaceuticals

69

Number of Employees

$12.9M

Revenue (est)

9

Current Jobs

33%

Employee Growth %

$101.3M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Mission Bio
$7.4M6944%
Rigel Pharmaceu...
$40.5M2714%
ProTrials Resea...
$25.6M1703%
Advanced Cell D...
$23.9M1668%
CellMax Life
$10M379%$9M
Atreca
$10.7M8117%
Full Spectrum A...
$5.7M395%
Pipette.com/Acc...
N/AN/A
Irvine Scientif...
$29.1M2059%
Talis Biomedica...
$8.1M544%

Mirati Therapeutics News

24-Aug-19 - Mirati Therapeutics Inc (MRTX) President & CEO Charles M Baum Sold $4.5 million of Shares

Mirati Therapeutics Inc is a biotechnology company. The company's focuses on precision medicine for oncology therapeutics. The company ...

24-Aug-19 - Buy, Sell or Hold? Detail Analysis Funko, Inc. (FNKO) or At Mirati Therapeutics, Inc. (MRTX)?

The shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX), has jumped by 116.74% year to date as of 08/21/2019. The shares currently trade at ...

24-Aug-19 - Leerink Swann Analysts Give Mirati Therapeutics (NASDAQ:MRTX) a $118.00 Price Target

Leerink Swann set a $118.00 price target on Mirati Therapeutics (NASDAQ:MRTX) in a research report sent to investors on Wednesday, July ...

Mirati Therapeutics Funding

DateAmountRoundLead InvestorsReference
2013-10-17$UndisclosedUndisclosedLeerink Swann LLCArticle
2013-10-24$56.9MUndisclosedJefferies LLCArticle
2015-09-15$80.0MUndisclosedCitigroupArticle
2015-09-16$101.3MUndisclosedCitigroupArticle
2017-01-09$65.0MUndisclosedLeerink PartnersArticle
2017-11-21$92.0MUndisclosedCowenArticle
2018-06-12$139.2MUndisclosedCowenArticle
2019-01-17$115.0MUndisclosedMultipleArticle
2019-01-23$130.0MUndisclosedMultipleArticle

Mirati Therapeutics Executive Hires

DateNameTitleReference
2016-01-11Marcy GrahamVP Investor Relations/Corporate CommunicationsArticle
2016-03-24Jamie DonadioSVP/CFOArticle
2016-10-05Chris LeMastersExecutive Vice President/Chief Business OfficerArticle